Grufity logoGrufity logo

NVAX

16.52USD-0.33(-1.96%)Market Closed

Novavax Inc

Market Summary

USD16.52-0.33Market Closed
-1.96%

NVAX Alerts

NVAX Stock Price

RSI Chart

Valuation

Market Cap

1.8B

Price/Earnings

-1.22

Price/Sales

1.39

Price/Cashflow

-2.42

MarketCap/EBT

-1.24

Price/Sales

Profitability

Operating Margin

55.65%

EBT Margin

-112.25%

Return on Equity

-2.3K%

Return on Assets

-56.26%

Fundamentals

Revenue

Revenue (TTM)

1.8B

Revenue Y/Y

310.74%

Revenue Q/Q

295.09%

Earnings

Earnings (TTM)

-1.3B

Earnings Y/Y

47.71%

Earnings Q/Q

66.97%

Price Action

52 Week Range

15.53236.50
(Low)(High)

Last 7 days

-0.1%

Last 30 days

-19.4%

Last 90 days

-45.6%

Trailing 12 Months

-89.8%

Financial Health

Current Ratio

0.99

Investor Care

Shares Dilution (1Y)

3.83%

Diluted EPS (TTM)

-17.81

Peers (Alternatives to Novavax)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
146.5B
26.3B
6.86% 46.41%
22.27
5.55
2.18% 21.86%
99.4B
27.1B
14.32% 33.87%
24.02
3.61
-1.26% -54.91%
59.1B
23.0B
22.70% -39.52%
4.2
2.57
227.55% 302.16%
41.3B
10.4B
7.38% 30.80%
14.4
3.98
-6.64% 85.32%
11.1B
1.4B
3.89% 57.25%
905.99
8.52
29.86% -86.92%
MID-CAP
3.7B
112.4M
6.18% -26.69%
-12.87
32.5
-41.50% -607.58%
3.4B
-
7.39% -35.47%
-14.65
59.51
215916.67% 21.41%
2.1B
68.3M
4.34% -60.25%
-8.33
30.98
42.18% -19.70%
2.0B
432.8M
45.87% -20.63%
29.99
4.9
1042.97% 128.67%
SMALL-CAP
1.8B
1.8B
-19.41% -89.80%
-1.22
1.39
53.41% -22.97%
1.6B
69.7M
-4.82% -76.34%
-3.15
20.84
745.14% -7.72%
891.0M
3.2M
5.78% -29.88%
-6.7
275.59
11.14% -46.59%
692.0M
114.2M
-14.32% -56.80%
-4.02
6.06
-17.11% -27.41%
458.1M
-
-17.48% -90.68%
-13.56
44.06
522.71% -129.91%
218.9M
-
-15.58% -80.57%
-2.36
609.63
-71.03% -64.56%

Financials for Novavax

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Revenue43.0%1,8471,2911,4031,1461,204
  S&GA Expenses12.3%411366331298275
  R&D Expenses-5.1%1,9402,0442,3252,5351,973
Earnings Before Taxes10.4%-1,298.81-1,449.06-1,288.76-1,714.54-1,062.42
Net Income10.4%-1,321.97-1,475.79-1,317.62-1,743.75-1,075.03
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets-13.6%2,2672,6232,8352,5772,566
  Current Assets-17.6%1,7602,1362,3472,1552,174
    Cash Equivalents-6.9%1,2811,3761,5711,5151,937
  Inventory-67.8%822561079-
  Net PPE0.4%256255247229215
  Goodwill-4.8%118123131131132
Liabilities-6.8%2,8333,0402,7702,9282,105
  Current Liabilities-22.6%1,6682,1562,2612,3901,753
Shareholder's Equity-35.7%-565.98-416.9565-351.67461
  Retained Earnings-4.3%-4,093.64-3,925.03-3,414.54-3,617.95-2,771.67
  Additional Paid-In Capital1.0%3,6413,6053,5663,3523,311
Accumulated Depreciation-30----
Shares Outstanding0.4%7878787675
* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations13.9%-640.53-743.96-428.65323537
  Share Based Compensation-9.2%135148163184202
Cashflow From Investing-24.8%-87.28-69.96-58.2810085
Cashflow From Financing-17.3%738845462927

Risks

What is the probability of a big loss on NVAX?

100%


Probability that Novavax stock will be more than 20% underwater in next one year

100%


Probability that Novavax stock will be more than 30% underwater in next one year.

95%


Probability that Novavax stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does NVAX drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Novavax was unfortunately bought at previous high price.

Returns

Cumulative Returns on NVAX

-7.8%


10-Year Cumulative Returns

-28.6%


7-Year Cumulative Returns

-10.4%


5-Year Cumulative Returns

51.3%


3-Year Cumulative Returns

What are the long-term rolling returns for NVAX?

FIve years rolling returns for Novavax.

Which funds bought or sold NVAX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
REDUCED
-0.42
-3,285,000
1,788,000
-%
2022-11-18
SevenOneSeven Capital Management
SOLD OFF
-100
-262,000
-
-%
2022-11-18
Ambassador Advisors, LLC
ADDED
44.63
-2,013,000
2,109,000
0.50%
2022-11-17
CENTRAL TRUST Co
UNCHANGED
-
-3,000
2,000
-%
2022-11-16
CAPTRUST FINANCIAL ADVISORS
SOLD OFF
-100
-345,000
-
-%
2022-11-16
Neo Ivy Capital Management
NEW
-
37,000
37,000
0.10%
2022-11-16
Front Row Advisors LLC
NEW
-
4,000
4,000
-%
2022-11-15
Balyasny Asset Management LLC
NEW
-
357,000
357,000
-%
2022-11-15
PUBLIC EMPLOYEES RETIREMENT ASSOCIATION OF COLORADO
UNCHANGED
-
-262,000
143,000
-%
2022-11-15
STATE STREET CORP
ADDED
23.21
-86,057,000
66,529,000
-%

1–10 of 41

Latest Funds Activity

Are funds buying NVAX calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own NVAX

Novavax News

Marketscreener.com

Novavax to Participate in BofA Securities 2022 Virtual Biotech SMID Cap Conference.2 days ago

The Motley Fool

The Motley Fool

NVAX Fair Value

Recent SEC filings of Novavax

View All Filings
Date Filed Form Type Document
Nov 21, 2022
8-K
Current Report
Nov 09, 2022
10-Q
Quarterly Report
Nov 08, 2022
8-K
Current Report
Nov 01, 2022
3
Insider Trading
Nov 01, 2022
4
Insider Trading
Nov 01, 2022
8-K
Current Report
Oct 06, 2022
8-K
Current Report
Sep 28, 2022
4
Insider Trading
Sep 28, 2022
4
Insider Trading
Sep 28, 2022
4
Insider Trading

Latest Insider Trading transactions for NVAX

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-09-26
Erck Stanley C
SOLD FOR TAXES
-41,136.6
18.87
-2,180
President and CEO
2022-09-26
Herrmann John A III
SOLD FOR TAXES
-24,983.9
18.87
-1,324
EVP, Chief Legal Officer
2022-09-26
Trizzino John
SOLD FOR TAXES
-32,248.8
18.87
-1,709
EVP, CCO and CBO
2022-09-26
Erck Stanley C
ACQUIRED
-
-
6,546
President and CEO
2022-09-26
Herrmann John A III
SOLD FOR TAXES
-4,868.46
18.87
-258
EVP, Chief Legal Officer
2022-09-26
Trizzino John
ACQUIRED
-
-
3,538
EVP, CCO and CBO
2022-09-26
Herrmann John A III
ACQUIRED
-
-
3,973
EVP, Chief Legal Officer
2022-09-26
Herrmann John A III
ACQUIRED
-
-
667
EVP, Chief Legal Officer
2022-08-24
Herrmann John A III
ACQUIRED
-
-
2,000
EVP, Chief Legal Officer
2022-08-24
Herrmann John A III
SOLD (Taxes)
-28,618
37.07
-772
EVP, Chief Legal Officer

1–10 of 50

NVAX Income Statement

2022-09-30
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Revenue:    
Revenues$ 734,577$ 178,844$ 1,624,473$ 924,090
Expenses:    
Cost of sales434,5930720,8740
Research and development304,297408,195977,4281,571,551
Selling, general, and administrative122,87677,793327,028214,144
Total expenses861,766485,9882,025,3301,785,695
Loss from operations(127,189)(307,144)(400,857)(861,605)
Other expense:    
Interest expense(4,169)(5,182)(15,279)(15,989)
Other expense(34,783)(4,064)(53,002)(7,267)
Loss before income tax expense(166,141)(316,390)(469,138)(884,861)
Income tax expense2,4726,0416,55212,606
Net loss$ (168,613)$ (322,431)$ (475,690)$ (897,467)
Earnings Per Share [Abstract]    
Basic (in usd per share)$ (2.15)$ (4.31)$ (6.13)$ (12.13)
​Weighted average number of common shares outstanding    
Basic (in shares)78,27474,74577,63173,972
Product sales    
Revenue:    
Revenues$ 626,091$ 0$ 1,267,174$ 0
Grants    
Revenue:    
Revenues106,273135,007313,348854,390
Royalties and other    
Revenue:    
Revenues$ 2,213$ 43,837$ 43,951$ 69,700

NVAX Balance Sheet

2022-09-30
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 1,280,581$ 1,515,116
Restricted cash10,78511,490
Accounts receivable111,645454,993
Inventory82,4328,872
Prepaid expenses and other current assets274,522164,648
Total current assets1,759,9652,155,119
Property and equipment, net255,532228,696
Right of use asset, net108,54340,123
Intangible assets, net8,4564,770
Goodwill117,535131,479
Other non-current assets17,40616,566
Total assets2,267,4372,576,753
Current liabilities:  
Accounts payable144,997127,050
Accrued expenses551,069673,731
Deferred revenue404,7761,422,944
Current portion of finance lease liabilities82,095130,533
Convertible notes payable324,5250
Other current liabilities160,49936,061
Total current liabilities1,667,9612,390,319
Deferred revenue1,035,418172,528
Convertible notes payable0323,458
Non-current finance lease liabilities31,4740
Other non-current liabilities98,56942,121
Total liabilities2,833,4222,928,426
Commitments and contingencies (Note 14)
Stockholders' equity (deficit):  
Common stock, $0.01 par value, 600,000,000 shares authorized at September 30, 2022 and December 31, 2021; and 79,204,509 shares issued and 78,476,814 shares outstanding at September 30, 2022 and 76,433,151 shares issued and 75,841,171 shares outstanding at December 31, 2021792764
Additional paid-in capital3,640,5973,351,967
Accumulated deficit(4,093,640)(3,617,950)
Treasury stock, cost basis, 727,695 shares at September 30, 2022 and 591,980 shares at December 31, 2021(89,940)(85,101)
Accumulated other comprehensive loss(23,794)(1,353)
Total stockholders’ deficit(565,985)(351,673)
Total liabilities and stockholders’ deficit$ 2,267,437$ 2,576,753